In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity
and mortality worldwide. Due to its large public health and societal implications, multidrug-…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

To the Editor—The unprecedented pace of vaccine development and deployment has been
instrumental in controlling the COVID-19 pandemic, at least in high-income countries. Even …

The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or
placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), …

Outbreaks of viral hemorrhagic fever caused by filoviruses have become more prevalent in
recent years, with outbreaks of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (…

Eukaryotic DNA replication requires the assembly of multiprotein pre-replication complexes (pre-RCs)
at chromosomal origins of DNA replication. Here we describe the interactions of …